Related Experiment Video
Updated: Jun 4, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Predictors of positive sentinel lymph node in thin melanoma
David V Yonick1, Rana M Ballo, Estelle Kahn
1Division of Surgical Oncology, Department of Surgery, Loyola University Medical Center, Maywood, IL, USA.
American Journal of Surgery
|March 4, 2011
Summary
Sentinel lymph node biopsy (SLNB) may be used for thin melanoma. Ulceration and thickness >.75 mm are key predictors of a positive sentinel lymph node biopsy (SLNB) in melanoma patients.
Area of Science:
- Dermatology
- Surgical Oncology
- Pathology
Background:
- Sentinel lymph node biopsy (SLNB) is a treatment option for thin melanoma (Breslow thickness <1.0 mm).
- The clinical utility of SLNB for thin melanoma is a subject of ongoing debate.
- Identifying factors predictive of SLN positivity is crucial for patient selection.
Purpose of the Study:
- To identify pathologic factors associated with sentinel lymph node positivity in patients with thin melanoma.
- To provide evidence-based guidance on the selection of thin melanoma patients who may benefit from SLNB.
Main Methods:
- Retrospective analysis of a prospective database.
- Inclusion of 1,199 patients diagnosed with primary cutaneous melanoma.
- Application of multiple logistic regression to identify predictors of SLN positivity.
Main Results:
- Thin melanomas (<1.0 mm) were diagnosed in 469 patients (39%).
- Of these, 147 patients (31%) underwent SLNB, with 16 patients (11%) having positive SLNs.
- Ulceration (OR, 5.27; P = .047) and thickness (OR, 46.69; P = .022) were significantly associated with SLN positivity.
Conclusions:
- Patients with thin melanomas measuring >.75 mm should be considered for SLNB.
- The presence of ulceration in thin melanomas is also an indicator for considering SLNB.
- These findings aid in refining patient selection for SLNB in thin melanoma.
